Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q03692
UPID:
COAA1_HUMAN
Alternative names:
-
Alternative UPACC:
Q03692; A1L4P2
Background:
Collagen alpha-1(X) chain, a pivotal component of the extracellular matrix, is synthesized by hypertrophic chondrocytes. It localizes to areas poised for mineralization in hyaline cartilage, playing a crucial role in skeletal development and integrity.
Therapeutic significance:
Mutations in this protein lead to Schmid type metaphyseal chondrodysplasia, characterized by short stature, coxa vara, and a waddling gait. Understanding the role of Collagen alpha-1(X) chain could open doors to potential therapeutic strategies for this and related skeletal disorders.